🔎 Trials Near Me

Početna › B-stanični limfom › Kalifornija

Kliničke studije za B-stanični limfom u državi Kalifornija

20 studija za B-stanični limfom traži sudionike na lokacijama u državi Kalifornija.

Gradovi u državi Kalifornija

Službeni tekst studije (engleski)

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

  • University of California, Davis, Sacramento
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 1. lis 2026. · NCT06343311

A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

  • Ucsf Fresno, Fresno
  • Kaiser Permanente Southern California, Irvine
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT06742996

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

  • Providence Medical Foundation, Fullerton
  • Cancer and Blood Specialty Clinic, Los Alamitos, Los Alamitos
  • UCLA, Santa Monica
  • i još 1
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 28. ruj 2026. · NCT07439653

Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study

  • City of Hope Medical Center, Duarte
  • City of Hope at Irvine Lennar, Irvine
U tijeku regrutacijaFaza 2
Od 60 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT06052826

A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )

  • City of Hope, Duarte
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2026. · NCT07101328

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

  • Research Site, Duarte
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 11. ruj 2026. · NCT06526793

A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

  • University of Southern California Norris Comprehensive, Los Angeles
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 11. ruj 2026. · NCT06634589

Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma

  • City of Hope Comprehensive Cancer Center, Duarte
  • University of California Davis Comprehensive Cancer Center, Sacramento
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 10. ruj 2026. · NCT05272384

A Study of ARC-02 in B-cell NHL

  • Start Cala, Los Angeles
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 26. kol 2026. · NCT07691606

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

  • University of California-Irvine Medical Center, Irvine
  • Cedars-Sinai Medical Center, Los Angeles
  • University of California, Los Angeles (UCLA) Medical Center, Los Angeles
  • i još 1
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT05826535

A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

  • Pacific Cancer Medical Center, Inc, Anaheim
  • TOI Clinical Research, Cerritos
  • Stanford School of Medicine-Cancer Clinical Trials Office, Palo Alto
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 17. kol 2026. · NCT05254743

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

  • City of Hope, Duarte
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 17. kol 2026. · NCT06528301

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Cedars-Sinai Medical Center, Los Angeles
  • University of California, Los Angeles (UCLA), Los Angeles
  • University of California, Irvine, Orange
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 4. kol 2026. · NCT07188558

DALY II USA/ MB-CART2019.1 for DLBCL

  • UC San Diego Health, La Jolla
  • Stanford University, Stanford
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 13. srp 2026. · NCT04792489

Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

  • Stanford Medical Center, Stanford
U tijeku regrutacijaFaza 2
Od 15 godina i više · Oba spola · Ažurirano 27. svi 2026. · NCT06954805

The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies

  • City of Hope, Duarte
  • Los Angeles Cancer Network, Los Angeles
  • UCLA Medical Center of Hematology/Oncology, Los Angeles
  • i još 1
U tijeku regrutacijaFaza 1/2
Od 12 do 95 godina · Oba spola · Ažurirano 15. tra 2026. · NCT04329728

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) for the Treatment of Intermediate or High Grade B-Cell Non-Hodgkin Lymphoma

  • City of Hope Medical Center, Duarte
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 5. ožu 2026. · NCT05801913

Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma

  • City of Hope Medical Center, Duarte
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 23. velj 2026. · NCT05432635

BAFFR-targeting CAR T Cells for Patients With Relapsed or Refractory B-NHL

  • City of Hope Medical Center, Duarte
  • Stanford University, Stanford
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 20. stu 2025. · NCT05370430

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

  • Children's Hospital Los Angeles, Los Angeles
  • Children's Hospital Orange County, Orange
  • UCSF School of Medicine, San Francisco
U tijeku regrutacijaFaza 1
Od 1 do 21 godina · Oba spola · Ažurirano 6. pro 2024. · NCT05476770

Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.